EP1226250A2 - Nouveaux polypeptides de type gpcr-kd5 et sequences d'adn correspondantes - Google Patents

Nouveaux polypeptides de type gpcr-kd5 et sequences d'adn correspondantes

Info

Publication number
EP1226250A2
EP1226250A2 EP00983092A EP00983092A EP1226250A2 EP 1226250 A2 EP1226250 A2 EP 1226250A2 EP 00983092 A EP00983092 A EP 00983092A EP 00983092 A EP00983092 A EP 00983092A EP 1226250 A2 EP1226250 A2 EP 1226250A2
Authority
EP
European Patent Office
Prior art keywords
polypeptide
polynucleotide
sequence
seq
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00983092A
Other languages
German (de)
English (en)
Inventor
Klaus DÜCKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to EP00983092A priority Critical patent/EP1226250A2/fr
Publication of EP1226250A2 publication Critical patent/EP1226250A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • G-proteins themselves, effector proteins, e.g., phospholipase C, adenyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M.I., et al., Science, 1991 , 252:802-8).
  • effector proteins e.g., phospholipase C, adenyl cyclase, and phosphodiesterase
  • actuator proteins e.g., protein kinase A and protein kinase C (Simon, M.I., et al., Science, 1991 , 252:802-8).
  • G-protein coupled receptors can be intracellularly coupled by heterot meric G-proteins to various intracellular enzymes, ion channels and transporters (see, Johnson et al., Endoc. Rev., 1989, 10:317-331)
  • Different G-protein a-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell.
  • Phosphorylation of cytoplasmic residues of G- protein coupled receptors have been identified as an important mechanism for the regulation of G-protein coupling of some G-protein coupied receptors.
  • G-protein coupled receptors are found in numerous sites within a mammalian host.
  • the present invention relates to GPCR_KD5, in particular GPCR_KD5 polypeptides and GPCR_KD5 polynucleotides, recombinant materials and methods for their production.
  • Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, hereinafter
  • Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation form naturally occuring sources, from genetically engineered host cells comprising expression systems (vide infra) or by chemical synthesis, using for instance automated peptide synthesisers, or a combination of such methods.
  • Means for preparing such polypeptides are well understood in the art.
  • Screening kits for use in the above described methods form a further aspect of the present invention.
  • Such screening kits comprise:
  • an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described.
  • “Homolog” is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms “ortholog”, and “paralog”. "Ortholog” refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog” refers to a polynucleotideor polypeptide that within the same species which is functionally similar.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des polypeptides et des polynucléotides de type GPCR_KD5 ainsi que des procédés de production de tels polypeptides au moyen de techniques de recombinaison. L'invention concerne également des procédés d'utilisation de ces polypeptides et de ces polynucléotides de type GPCR_KD5 dans des doses diagnostiques.
EP00983092A 1999-11-03 2000-10-26 Nouveaux polypeptides de type gpcr-kd5 et sequences d'adn correspondantes Withdrawn EP1226250A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00983092A EP1226250A2 (fr) 1999-11-03 2000-10-26 Nouveaux polypeptides de type gpcr-kd5 et sequences d'adn correspondantes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99121786 1999-11-03
EP99121786 1999-11-03
PCT/EP2000/010564 WO2001032864A2 (fr) 1999-11-03 2000-10-26 Nouveaux polypeptides de type gpcr_kd5 et sequences d'adn correspondantes
EP00983092A EP1226250A2 (fr) 1999-11-03 2000-10-26 Nouveaux polypeptides de type gpcr-kd5 et sequences d'adn correspondantes

Publications (1)

Publication Number Publication Date
EP1226250A2 true EP1226250A2 (fr) 2002-07-31

Family

ID=8239324

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00983092A Withdrawn EP1226250A2 (fr) 1999-11-03 2000-10-26 Nouveaux polypeptides de type gpcr-kd5 et sequences d'adn correspondantes

Country Status (4)

Country Link
EP (1) EP1226250A2 (fr)
JP (1) JP2003513629A (fr)
CA (1) CA2388308A1 (fr)
WO (1) WO2001032864A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US7816492B2 (en) 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
ATE348162T1 (de) * 2000-05-18 2007-01-15 Bayer Healthcare Ag Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor.
US20030180813A1 (en) * 2000-12-01 2003-09-25 Takahide Ohishi Method of screening remedy for diabetes
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
WO2009038974A1 (fr) 2007-09-20 2009-03-26 Irm Llc Composés et compositions en tant que modulateurs de l'activité de gpr119

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645717A1 (fr) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Recepteurs humains couples a la proteine g orphan
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0132864A2 *

Also Published As

Publication number Publication date
WO2001032864A3 (fr) 2001-12-06
WO2001032864A2 (fr) 2001-05-10
CA2388308A1 (fr) 2001-05-10
JP2003513629A (ja) 2003-04-15

Similar Documents

Publication Publication Date Title
WO2001014577A1 (fr) Clonage moleculaire d'une galanine comme recepteur 7tm (axor40)
WO2001016159A1 (fr) Gpcr, ant
US20070207506A1 (en) G-protein coupled receptor and DNA sequences thereof
EP1203023A1 (fr) Polypeptides pgpcr-3 et leurs sequences d'adn
WO2001032864A2 (fr) Nouveaux polypeptides de type gpcr_kd5 et sequences d'adn correspondantes
WO2001053308A1 (fr) Clonage d'un recepteur 7tm d'un singe (axor8)
WO2001042486A1 (fr) Axor12
US20040071695A1 (en) Novel g-protein coupled receptor
EP1226247A1 (fr) Polypeptides du type gp27 et leurs sequences d'adn
AU2001283930B2 (en) Novel g-protein coupled receptor
AU2001281836B2 (en) A g-protein coupled receptor
US20050054034A1 (en) Thyrotropin-releasing hormone receptor-like gpcr(gprfwki)
WO2001053337A1 (fr) Recepteur humain axor33 7 fois transmembranaire
WO2001064836A2 (fr) Clonage d'un variant de gpr38
US20060154244A1 (en) Novel g-protein coupled receptor
US20040106149A1 (en) Novel gpcr hfrbn63
WO2001038348A2 (fr) Recepteur htogh35 couple a la proteine g
WO2001025280A1 (fr) Paul, recepteur couple a une proteine g
WO2001068665A1 (fr) Variant-1 du gene h3 de l'histamine humaine
WO2001061003A1 (fr) Homologue humain du flamingo
AU2001281836A1 (en) A g-protein coupled receptor
WO2001036484A1 (fr) Nouveaux polypeptides recepteurs olfactifs et sequences d'adn de ces polypeptides
WO2001014410A1 (fr) Clonage d'un recepteur 7tm de type pafr (axor11)
AU2001283930A1 (en) Novel g-protein coupled receptor
WO2001016177A1 (fr) Recepteurs couples par la proteine g ou recepteurs a 7 regions transmembranaires de souris ou canoman

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041214